TTY Biopharm Co Ltd (4105) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.088x

Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has a cash flow conversion efficiency ratio of 0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$654.16 Million ≈ $20.61 Million USD) by net assets (NT$7.40 Billion ≈ $233.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4105 market cap overview for the company's overall valuation and market capitalisation.

TTY Biopharm Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how TTY Biopharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

TTY Biopharm Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TTY Biopharm Co Ltd ranked by their cash flow conversion efficiency. Explore 4105 cash flow quality score to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Shenzhen Guangju Energy Co Ltd SHE:000096	0.003x
Meorient SHE:300795	0.027x
Shandong Wohua Pharmaceutical Co Ltd SHE:002107	0.028x
Envela Corp NYSE MKT:ELA	0.279x
Beijing Science Sun Pharmaceutical Co Ltd SHE:300485	0.009x
Hamaton Automotive Technology Co Ltd SHE:300643	0.035x
Mühlbauer Holding AG XETRA:MUB	0.156x
Lotte Tour Dev KO:032350	-0.024x

Annual Cash Flow Conversion Efficiency for TTY Biopharm Co Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of TTY Biopharm Co Ltd from 2017 to 2025. View 4105 stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$8.05 Billion ≈ $253.66 Million	NT$1.76 Billion ≈ $55.51 Million	0.219x	+21.80%
2024-12-31	NT$7.51 Billion ≈ $236.64 Million	NT$1.35 Billion ≈ $42.51 Million	0.180x	+7.70%
2023-12-31	NT$6.51 Billion ≈ $204.98 Million	NT$1.09 Billion ≈ $34.19 Million	0.167x	-15.86%
2022-12-31	NT$6.23 Billion ≈ $196.38 Million	NT$1.24 Billion ≈ $38.93 Million	0.198x	-8.99%
2021-12-31	NT$5.77 Billion ≈ $181.70 Million	NT$1.26 Billion ≈ $39.58 Million	0.218x	+151.55%
2020-12-31	NT$6.08 Billion ≈ $191.49 Million	NT$526.35 Million ≈ $16.58 Million	0.087x	-55.84%
2019-12-31	NT$6.17 Billion ≈ $194.36 Million	NT$1.21 Billion ≈ $38.12 Million	0.196x	+16.74%
2018-12-31	NT$6.39 Billion ≈ $201.37 Million	NT$1.07 Billion ≈ $33.83 Million	0.168x	+3.03%
2017-12-31	NT$6.11 Billion ≈ $192.55 Million	NT$996.52 Million ≈ $31.40 Million	0.163x	--

About TTY Biopharm Co Ltd

TWO:4105 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$618.87 Million

NT$19.64 Billion TWD

Market Cap Rank

#11322 Global

#402 in Taiwan

Share Price

NT$79.00

Change (1 day)

-0.13%

52-Week Range

NT$72.10 - NT$86.30

All Time High

NT$97.91